Eli Lilly beats on Q2 revenue and profit driven by 'a collection' of name brand drug sales: Analyst

Pharma giant Eli Lilly's (LLY) stock is soaring after reporting a second-quarter earnings beat, boasting revenue of $8.31 billion and earnings of $2.11 per share. Raising its full-year guidance, the pharmaceutical company attributes its success to sales of its diabetes and weight-loss drug, Mounjaro, and breast cancer pill, Verzenio. Verzenio is "a drug that's not only producing a blockbuster type of revenue, but growing at north of 50% in the quarter," Lee Brown, ThirdBridge Global Sector Lead for Healthcare, told Yahoo Finance Live. Brown also discusses the adoption of diabetes drugs doubling as a weight-loss drugs, highlighting certain health benefits, and stating "the cultural reaction has been one that's been embraced."
#youtube #yahoofinance #stockmarket
Subscribe to Yahoo Finance: yhoo.it/2fGu5Bb
About Yahoo Finance:
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
To learn more about Yahoo Finance Plus please visit: yhoo.it/33jXYBp
Connect with Yahoo Finance:
Get the latest news: yhoo.it/2fGu5Bb
Find Yahoo Finance on Facebook: bit.ly/2A9u5Zq
Follow Yahoo Finance on Twitter: bit.ly/2LMgloP
Follow Yahoo Finance on Instagram: bit.ly/2LOpNYz
Follow Yahoo Finance Premium on Twitter: bit.ly/3hhcnmV

[@hollykelley2369]

A BILLION . WOW !

[@VernCrisler]

Some useful and thankfully accurate information about these GLP / GIP drugs.